Connect with us

News

Short Sellers Don’t Want Gilead’s Remdesivir to Succeed (Opinion)

A COVID-19 opinion piece not to pass up…

Published

on

We know that the FDA has not approved any drug for the Treatment of COVID-19. We have, however, brought the virus under control through social distancing, masks, and staying home. We have been told that if we had not done these things, millions would have died. We will never know if that is a true statement or not.

I have written many times about the 7,800 people on average who die daily of many different causes in the ordinary course of events. The original coronavirus model forecast that first came out called for a total of 500,000 Brits and 2.3 million Americans who would die from COVID-19. This now has been revised to less than 20,000 Brits and around 60,000 Americans. If these numbers hold, the death rate will about equal a strong flu season. Until now, we never brought the world economy to a halt over any flu pandemic since 1917-18, regardless of the number of deaths.

Most experts believe it will take 12 to 18 months before we have an approved vaccine. Until a vaccine is available, the people of the world will have lingering thoughts about going out and reengaging with their neighbors, friends, and coworkers.

There are many drugs under development that could treat the symptoms and, in some cases, kill the virus so that people could recover. One of those drugs under review was developed by Gilead and is called Remdesivir. It is an antiviral. In simple terms, it seems to prevent the virus from multiplying. As it was explained to me in layman terms, the virus is like the carburetor for an engine. The engine needs fuel and oxygen to run, and if the engine can’t get that fuel and air, it can’t run. Remdesivir blocks the fuel and oxygen from getting into the virus.

take our poll - story continues below

Who would you vote for if the elections were held today?

  • Who would you vote for if the elections were held today?  

  • This field is for validation purposes and should be left unchanged.
Completing this poll grants you access to Flag And Cross updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

The drug has been used successfully in compassionate care use when a person was in danger of dying. Recently, results of two clinical trials appeared first in the New England Journal of Medicine and second, in Time. While both were small trials and didn’t meet the definition of a clinical trial, the results were to my mind amazing. The report said, “Of 125 patients in the University of Chicago Medicine study, 113 had severe disease,” meaning they had difficulty breathing. Kathleen Mullane, a professor of medicine at the university who is overseeing the trial, said “most of the patients taking the drug had improved enough to be discharged from the hospital, and only two died.”

This last study at other institutions was reported after the close of the market on Thursday, April 16, and almost immediately Gilead shot up $13 a share. On Friday morning, I received 6 messages that warned people not to put too much value in the latest report. The stock, while still closing up $7.45 for the day, was down $6 from its overnight high. The 10-day average of share volume was 16.6 million shares. On Friday, the volume was 93.1 million shares. 

Was it possible that some of the people who cautioned before the market opened were short overnight and were trying to drive the price of the stock down? They would do this so they could cover the short within a few days and make a great deal of money. For those of you who don’t know, in the trade, this is called talking a stock down. 
 
In full disclosure, my clients and I have owned Gilead for over 10 years. What concerns me is that the people in the world need something to hang on to so that if one got sick, there would be something that could save a life. If the additional clinical trials reporting between now and the end of May have similar results to the ones referred to in this article, Remdesivir will be an economic game-changer for the world. If we know we can kill it before it kills us, we can quickly restore the global economy.

I don’t know what will happen; only time will tell, but all the evidence points to a massive breakthrough. If the other clinical trials prove anywhere near as favorable, the naysayers will recommend the purchase of the stock. By that time, though, the price will be much higher.

This should not be considered a recommendation for the purchase of Gilead stock. Do your own research and talk to your financial advisor to see if Gilead is right for you. One last thing, nobody has paid me to write this article; all investments contain risk. 

Dan Perkins is a published author of 4 novels on nuclear and biological terrorism against the United States and is a current events commentator for over 20 news blogs. He appears on radio and TV between 40 and 60 times a month, depending on the news cycles, and on about 1,400 radio stations and TV networks. He is either a guest host or host on 4 weekly syndicated talk shows. Dan’s newest show is called “America’s Cannabis Conversation” on the W420radionetwork.com, a new show that broadcasts Saturday each week at 4:20 PM local time. More information on Perkins can be found at his web site danperkins.guru.

News

Vaccine Manufacturer Now Says Three Shots Required to Fend Off Omicron

At what point will this all end?

Published

on

Our third COVID-19 winter is now arriving, and there appear to be varying ideas about just what the world should expect.

Winter time has long brought about fears of an increased spread of the illness, thanks to the fact that many more folks will the gathering indoors, where the virus will have an opportunity to spread with less resistance.

But the newest variant of the virus has been described as “mild” by the doctors most familiar with it, and even the normally-glum Dr. Anthony Fauci seems to have backed off of his earlier concerns a bit.

Pfizer this week released a statement suggesting that their vaccine, originally administered in two doses, will require a third shot to be effective against omicron.

take our poll - story continues below

Who would you vote for if the elections were held today?

  • Who would you vote for if the elections were held today?  

  • This field is for validation purposes and should be left unchanged.
Completing this poll grants you access to Flag And Cross updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

Preliminary lab studies show two doses of the Pfizer/BioNTech vaccine may not provide sufficient protection against the Omicron coronavirus variant, but three doses are able to neutralize it, the companies said in a news release on Wednesday.

Samples from people who had two doses of the Covid-19 vaccine saw, on average, a more than 25-fold reduction in neutralization ability against the Omicron variant than the earlier virus, “indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant,” the companies said.

The companies said two doses may still provide protection against severe disease.

“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” Pfizer Chairman and CEO Albert Bourla said in a statement. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”

The news is sure to elicit some grumbling from the masses, who are very much over the continued hysteria regarding COVID-19.

Our third COVID-19 winter is now arriving, and there appear to be varying ideas about just what the world should expect. Winter time has long brought about fears of an increased spread of the illness, thanks to the fact that many more folks will the gathering indoors, where the virus will have an opportunity to spread with less resistance. But the newest variant of the virus has been described as “mild” by the doctors most familiar with it, and even the normally-glum Dr. Anthony Fauci seems to have backed off of his earlier concerns a bit. Pfizer this week released a statement suggesting that their vaccine, originally administered in two doses, will require a third shot to be effective against omicron. Preliminary lab studies show two doses of the Pfizer/BioNTech vaccine may not provide sufficient protection against the Omicron coronavirus variant, but three doses are able to neutralize it, the companies said in a news release on Wednesday. Samples from people who had two doses of the Covid-19 vaccine saw, on average, a more than 25-fold reduction in neutralization ability against the Omicron variant than the earlier virus, “indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant,” the companies said. The companies said two doses may still provide protection against severe disease. “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” Pfizer Chairman and CEO Albert Bourla said in a statement. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.” The news is sure…

Continue Reading

Entertainment

Chris Cuomo Preparing Massive Lawsuit Aimed at Former Employer

But CNN INSTANTLY put the kibosh on it!

Published

on

Things over at CNN have been rough in recent days, and they certainly aren’t smoothing out anytime soon.

The infotainment network is facing an onslaught of trouble of late, thanks largely to the actions of Chris Cuomo – formerly the top draw at the station – thanks to his inappropriate actions in regard to his brother’s sexual assault scandal during his time as the Governor of New York.

Cuomo has since been fired, and a war of words has erupted between he and his former employer.  Just yesterday it was reported that CNN was rebuking Cuomo’s claims that they were aware of the poor behavior of their primetime star.

Today, Cuomo is setting himself up to sue CNN.

take our poll - story continues below

Who would you vote for if the elections were held today?

  • Who would you vote for if the elections were held today?  

  • This field is for validation purposes and should be left unchanged.
Completing this poll grants you access to Flag And Cross updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

Fired CNN host Chris Cuomo is set to sue the network if it balks at paying him at least $18 million to cover what’s left on his contract, sources told The Post on Monday.

Cuomo, 51, has hired lawyers and is preparing to file the lawsuit over the remainder of the four-year contract he signed last year — after a bitter back-and-forth about what the network knew of his secret efforts to aid his embattled brother, then-Gov. Andrew Cuomo, said sources familiar with the matter.

His contract was reportedly worth $6 million annually, leaving between $18 million and $20 million that he would be owed, sources said, adding that Chris Cuomo would also likely seek damages.

The network was not entertained by the idea.

But CNN has “no intention of paying [Chris] Cuomo a penny,” an insider said.

“If he gets a settlement, there would be uproar,” the source added.

Cuomo has also left his SiriusXM radio program this week, leaving the longtime anchor with no audience to complain to.

Things over at CNN have been rough in recent days, and they certainly aren’t smoothing out anytime soon. The infotainment network is facing an onslaught of trouble of late, thanks largely to the actions of Chris Cuomo – formerly the top draw at the station – thanks to his inappropriate actions in regard to his brother’s sexual assault scandal during his time as the Governor of New York. Cuomo has since been fired, and a war of words has erupted between he and his former employer.  Just yesterday it was reported that CNN was rebuking Cuomo’s claims that they were aware of the poor behavior of their primetime star. Today, Cuomo is setting himself up to sue CNN. Fired CNN host Chris Cuomo is set to sue the network if it balks at paying him at least $18 million to cover what’s left on his contract, sources told The Post on Monday. Cuomo, 51, has hired lawyers and is preparing to file the lawsuit over the remainder of the four-year contract he signed last year — after a bitter back-and-forth about what the network knew of his secret efforts to aid his embattled brother, then-Gov. Andrew Cuomo, said sources familiar with the matter. His contract was reportedly worth $6 million annually, leaving between $18 million and $20 million that he would be owed, sources said, adding that Chris Cuomo would also likely seek damages. The network was not entertained by the idea. But CNN has “no intention of paying [Chris] Cuomo a penny,” an insider said. “If he gets a settlement, there would be uproar,” the source added. Cuomo has also left his SiriusXM radio program this week, leaving the longtime anchor with no audience to complain to.

Continue Reading
The Schaftlein Report

Latest Articles

Best of the Week